[Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)]. / Bioverfügbarkeit von Theophyllin in einer neuen oralen Retardzubereitung.
Arzneimittelforschung
; 31(9): 1489-97, 1981.
Article
in De
| MEDLINE
| ID: mdl-7197962
ABSTRACT
On the basis of biopharmaceutic-pharmacokinetic and galenic aspects a new sustained-release preparation of theophylline according to the "divided-dose" principle was developed. The technological procedure used allows a reproducible manufacture of a stable product with narrow limits of pharmaceutical quality. The bioavailability of the sustained-release pellets in a dose corresponding to 350 mg active principle is examined in comparison to an aqueous solution or retard-tablet formulation on the marked (containing 260 mg drug/dose), respectively, after single or multiple dose administration to 7 healthy volunteers. The relative bioavailability of the new formulation is about 100%. During chronic application the controlled drug delivery from the sustained-release pellets warrants only slight fluctuations of plasma levels by avoiding peak concentrations. Formulations with a dosage of 200, 350 or 500 mg, respectively, allow adaptation of continuous plasma levels in the therapeutic range between 5--20 micrograms/ml according to the therapeutic necessities of a patient.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Theophylline
Type of study:
Prognostic_studies
Limits:
Adult
/
Humans
/
Male
Language:
De
Journal:
Arzneimittelforschung
Year:
1981
Document type:
Article